The United States Centers for Disease Control and Prevention estimates that approximately 14,000 persons in the United States die each year as a result of RSV. In addition, despite its status as one of the most common viral infections, RSV is not yet a reportable disease. In response to the magnitude of RSV, the newly released consensus report makes several priority recommendations. The report recommends: that the Centers for Disease Control and Prevention make RSV a reportable disease, that equal treatment be provided to infant children and other at-risk populations independent of their insurance status, and that physicians and other public health professionals participate in current ICD-10 coding discussions in order to guarantee that infants with RSV are properly diagnosed.
"The recent proposed change to the FDA approved dosage may have an unintended consequence of disproportionately affecting African American infants. Not only are African Americans over-represented among infants who are premature and/or low birth weight, they are also over-represented within the ranks of almost all other RSV risk factors," says Debra A. Toney, PhD, RN, FAAN, President, National Black Nurses Association.
While there is no vaccine for this disease, the possibility of hospitalization can be reduced in vulnerable, high risk populations such as premature and/or low birth weight babies by providing prophylactic doses of an agent known as Palivizumab. The recommended dosage was recently reduced for some at risk infants. However, the NMA/NBNA consensus panel recommends that more research is needed to confirm when fewer doses will achieve the same effect as a full season of prophylaxis. "Indeed, it is critical that these recommendations be implemented immediately," adds Willarda V. Edwards, M.D., M.B.A., Chair of the Consensus Panel and Immediate Past President of the National Medical Association.
To download a copy of the executive summary of the report visit www.NMAnet.org
